Erlotinib

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK: does not directly inhibit ERK1 or ERK2.A selective inhibitor of MEK and blocker of MAP.

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK: does not directly inhibit ERK1 or ERK2.A selective inhibitor of MEK and blocker of MAP.

InformationPelitinib (EKB-569) is a potent irreversibleEGFRinhibitor withIC50of 38.5 nM. Pelitinib (EKB-569) also slightly inhibitsSrc,MEK/ERKandErbB2with IC50s of 282 nM, 800 nM and 1255 nM, respectively. Phase2.In vitroPelitinib displays much

PhosphoDetectT Anti-MAP Kinase ERK1/ERK2 (pThr²⁰²

PHOSPHOTYROSINE ERBB3 / RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 ELISA KIT

PHOSPHOTYROSINE ERBB4 / RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 ELISA KIT

General description This kit provides enough dye for up to 50 samples of 20 million cells each and enough diluent for up to 30 samples of 20 million cells each when using a 2 mL final staining volume containing a final concentration of 2 x 10 -6

InformationRavoxertinib (GDC-0994) Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.In vitroGDC-0994 potently inhibits phospho-p90RSK in tumor

InformationSapitinib (AZD8931) is a reversible, ATP competitive inhibitor ofEGFR,ErbB2andErbB3withIC50of 4 nM, 3 nM and 4 nM in cell-free assays, more potent than Gefitinib or Lapatinib against NSCLC cell, 100-fold more selective for the ErbB family

A cell-permeable, potent, reversible, ATP-competitive, and specific inhibitor of human p38 MAP Kinase (IC 50 = 60 nM). Binds to an extended pocket in the active site of the enzyme.

SC68376 is a potent, reversible, cell-permeable, ATP-competitive, and selective inhibitor of p38 MAP kinase activity in a dose-dependent manner (IC|50|= 2-5 μM). Does not inhibit basal ERK or IL-1-induced JNK activity.

A potent, selective inhibitor of ERK1 and ERK2 (IC₅₀s = 4 and 1 nM, respectively) has nanomolar cytotoxicity in tumor cells with mutations in BRAF, NRAS, or KRAS effective in vivo, inducing regression of xenograft tumors in mice.